Table 1.
Panels of Samples
| Cohort | Status | Participants, No. | Samples, No. | PCR Positive, No. | Age, y, Median (Range) | Sex (% Male) | Days Post–Symptom Onset, Median (Range) |
|---|---|---|---|---|---|---|---|
| Établissement Français du Sang 1 | Negative panel: prepandemic controls | 45 | 45 | … | >18 | … | … |
| Établissement Français du Sang 2 | Negative panel: prepandemic controls | 213 | 213 | … | 42 (18–81) | 40% | … |
| Thai Red Cross | Negative panel: prepandemic controls | 68 | 68 | … | >18 | … | … |
| Peruvian donors | Negative panel: prepandemic controls | 81 | 81 | … | >18 | … | … |
| Hôpital Bichat (Paris, France) |
Positive panel: hospitalized patients | 2 | 8 | 2 | 31 (30–32) | 100% | 14 (8–24) |
| Hôpital Cochin (Paris, France) |
Positive panel: hospitalized patients | 64 | 64 | 64 | 55 (25–79) | 76% | 17 (10–28) |
| Strasbourg hospitals 1 | Positive panel: infected HCWs | 161 | 161 | 161 | 32 (20–62) | 31% | 24 (13–39) |
| Crépy-en-Valois, Feb–Mar 2020 | Positive panel: infected community members (flow cytometry positive) | 154 | 174 | 0 | 17 (15–56) | 34% | … |
| Dublin hospitals | Hospitalized patients | 194 | 213 | 194 | 55 (21–92) | 47% | 13 (1–126) |
| Strasbourg hospitals 2 | Follow-up of infected HCWs | 347 | 724 | 347 | 41 (21–74) | 23% | 132 (11–284) |
| Institut Mutualiste Montsouris (Paris, France) |
Seroprevalence survey in HCWs (unknown status) | 769 | 769 | 20 | 41 (18–72) | 27% | … |
| Institut Mutualiste Montsouris (Paris, France) |
Follow-up of seropositive HCWs | 29 | 29 | 12 | 37 (24–63) | 41% | 304 (285–336) |
| Crépy-en-Valois, Nov–Dec 2020 | Seroprevalence survey in community members (unknown status) | 725 | 725 | NA | NA | NA | NA |
Abbreviations: HCW, healthcare worker; NA, not available; PCR, polymerase chain reaction.